Deltex Medical Group plc
DEMG.L · LSE
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.02 | -0.27 | 0.12 |
| FCF Yield | -13.84% | -37.12% | -6.48% | -4.98% |
| EV / EBITDA | -12.11 | -6.01 | -26.78 | -25.37 |
| Quality | ||||
| ROIC | -9.31% | -12.38% | -11.96% | -8.48% |
| Gross Margin | 66.82% | 55.37% | 66.86% | 73.04% |
| Cash Conversion Ratio | 0.80 | 1.19 | 0.57 | -0.10 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.70% | -22.68% | -21.94% | -24.06% |
| Free Cash Flow Growth | 50.06% | -63.25% | -57.18% | 65.27% |
| Safety | ||||
| Net Debt / EBITDA | -4.11 | -2.02 | -5.62 | -5.11 |
| Interest Coverage | 0.00 | -5.72 | -4.59 | -3.86 |
| Efficiency | ||||
| Inventory Turnover | 0.54 | 0.45 | 0.43 | 0.43 |
| Cash Conversion Cycle | 137.67 | 175.19 | 99.50 | 112.54 |